R&D Projects
R&D Projects
Alpex is innovating every day to eradicate disease and treat illness.
Research is at the heart of our products’ success. As a research-based pharmaceutical company, we’re driving rapid growth and combating disease by developing innovative medicinal products.
LONGEVITY is also a DEFINING TREND OF THE FUTURE. We are addressing this mew focus by developing experitise and proprietary Life-Extending formulations to support the global aging populations in longevity.
It is our dedication to the undertaking of profuse R&D that underpins the therapeutic properties of Alpex pharmaceuticals and nutraceuticals. And is without a doubt what enabled us to become a reference name across the globe in our industry.
We dedicate a significant portion of our operational space to R&D activities, doing so in areas with significant demand and high-growth potential.
To date, and in addition to our first-party products, we have undertaken extensive development activities for various third-party pharma and nutraceutical companies. And In view of establishing licensing partnerships, we go above and beyond to ensure efficient operations and project success.
Our development plan includes drug-excipient compatibility studies, analytical method development, definition of formula, cleaning development, non-pivotal stability studies and reporting.
Patents & intellectual property
We currently hold over 100 pharma patents protecting our innovative products, their composition, formulations, and our proprietary technologies
Current R&D Projects
In the scope of a clearly articulated roadmap, we are currently working on X R&D projects that will enable us to further our range of offerings in a sensible manner. Among many, the following flagship projects are but a few of the projects that we are particularly excited about. With the first one being for a novelty drug planned to obtain approval in 2022.
- API/name: Orphan 001
- Dosage form: Sachet
- Indication: Rare Disease
- Market size: US$130.2 B by 2020, CAGR 2021-2028 2.5%.
- Approving authorities: Food and Drug Administration (FDA) approval expected December 2022.
- API/name: New unnamed Molecule
- Dosage form: Effervescent Tablet
- Indication: Crone’s Disease
- Market size: US $21.46 B by 2025, CAGR 2.4%.
- Approving authorities: US Clinical Trials FDA Approval Expected 2025 (currently in Phase 2)
Labs & Facilities
Our doors are open… welcome
Over the course of the past 20 years, we have invested more than 50 million dollars in a perpetual process of modernization of our facilities and infrastructure. Our labs and manufacturing facilities are a great source of pride at Alpex.
Pharma R&D And Manufacturing Facility
From a developmental to a commercial scale, and with a building Footprint of 7.762 m²; our facilities are well-equipped for the controlled handling of both anodyne and highly potent substances & materials.
Our Labs
Microbiology Lab
Physical Lab
Chemical Lab
Quality-Control Lab
Our labs are run by highly qualified scientists and technicians with long-running experience. Ensuring perfectly conducted procedures, from formulation to batch testing.